Incidence, Characteristics, and Management of Alpelisib-Associated Rash in Patients With Advanced Breast Cancer

Anisha B. Patel, MD^{1,a}; Lucia Seminario-Vidal, MD, PhD²

¹University of Texas MD Anderson Cancer Center, Houston, TX; ²H. Lee Moffitt Cancer Center, Tampa, FL

Authors contributed equally to this work ^aPresenting author

Synopsis

- Hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) breast cancer is the most common subtype of advanced breast cancer (ABC).¹
- ~40% of patients with HR+, HER2- breast cancer have mutations in the *PIK3CA* gene, which encodes the α subunit of phosphatidylinositol-3-kinase (PI3K).²⁻⁴
- PIK3CA mutations have been associated with the development of resistance to endocrine therapy, and are a negative prognostic factor in ABC.^{4,5}
- Alpelisib is an α -selective PI3K inhibitor approved in combination with fulvestrant for the treatment of patients with HR+, HER2- ABC with mutations in the PIK3CA gene who progressed on or after endocrine therapy.⁶
- U.S. Food & Drug Administration (FDA) approval of this combination was based on improved efficacy data compared with placebo plus fulvestrant, and a manageable safety profile reported in the Phase III SOLAR-1 trial (NCT02437318).
- Cutaneous toxicities, particularly the development of rash, are a class effect of PI3K pathway inhibitors and have been reported in up to 54% of patients treated with alpelisib.7-9

Objective

 The objective of this poster is to provide dermatologists with specific guidance on the management of alpelisib-associated dermatologic adverse events.

Methods

- This review of alpelisib-associated rash includes safety data from the SOLAR-1 trial, the BYLieve study, and a single-center retrospective study.
- SOLAR-1 evaluated alpelisib (300 mg QD) + fulvestrant (500 mg, every 28 days and once on day 15) or placebo + fulvestrant (equal dosing) in women or men with HR+, HER2- ABC who had progressed on or after prior aromatase inhibitor (N=572).
- BYLieve (NCT03056755), is an ongoing Phase II study evaluating alpelisib (300 mg QD) + fulvestrant (500 mg, every 28 days and once on day 15) or letrozole (2.5 mg QD) in women of any menopausal status and men with HR+, HER2-ABC and confirmed PIK3CA-mutant status who had progressed on or after prior treatments.¹⁰
- Results from Cohort A (N=127; cohort of patients previously treated with cyclin-dependent kinase [CDK]4/6 inhibitors) have recently been reported and are included here.
- A single-center retrospective study evaluated data from 4 randomized trials and postapproval treatment records involving ABC patients who received alpelisib-based treatments (most frequently combined with endocrine therapy, N=102), with the purpose of characterizing alpelisib-associated cutaneous toxicities and describing management strategies.¹¹
- · Alpelisib prescribing information and other available literature are also included.

Results

Incidence of Alpelisib-Associated Rash

- Clinical trials have reported an incidence of any-grade rash (by single preferred term) ranging from 28% to 36% (grade \geq 3 = 9%-10%) in alpelisib-treated patients.^{7,10}
- Rash led to treatment discontinuation in 3% to 4% of these patients.
- No grade 4 rash was reported in SOLAR-1 or in the retrospective study.^{7,9,11}

Characteristics of Rash

- In clinical studies, the median time to rash onset was approximately 2 weeks after starting alpelisib treatment.9,11
- In the retrospective study, median duration of rash was 7 days.¹¹
- In SOLAR-1, the median time to improvement by at least 1 grade in patients with grade \ge 3 rash was 11 days.9
- Rash is more frequently localized in the trunk (including chest, abdomen, and back) and extremities; rash on face and scalp is less common.11
- Rash events can be asymptomatic, or present symptoms such as burning pain or pruritus (more common in grade 3 rash).¹¹

- The vast majority of patients who develop alpelisib-associated rash present with maculopapular (morbilliform) rash; acneiform rash can also be observed. Characteristics of these 2 rash types are presented in Table 1.11
- Retrospective data from 2 patients who experienced alpelisib-associated rash showed histology consistent with a hypersensitivity reaction.¹¹
- Laboratory assessment data showed that patients who developed rash had an increase in blood eosinophils after 2 weeks of alpelisib treatment compared with baseline (2.7% vs 4.4%, P<0.05); a trend toward elevated ALT was also observed.¹¹
- No differences in lymphocyte, neutrophil, or monocyte counts were reported between patients who developed rash and those who did not.

Table 1. Characteristics of alpelisib-associated rash


Rash Type	Relative Incidence¹¹	Possible Symptoms ¹¹⁻¹³	Clinical Features ¹¹⁻¹⁵	Histopathologica Characterization ¹¹
Maculopapular (morbilliform)	26 of 29 patients in the alpelisib retrospective study (90%) experienced maculopapular rash; more common in patients receiving alpelisib plus hormone therapy	 Pruritic Burning sensation Tightness 	 Presence of macules and papules Centripetal distribution; mostly localized on upper trunk and extremities 	 Superficial perivasc dermatitis with focal mild interface chang or folliculocentric spongiosis May present with lymphocytic infiltrati
Acneiform	3 of 29 patients in the alpelisib retrospective study (10%) experienced acneiform rash; more common in patients with HER2+ BC receiving alpelisib plus trastuzumab and anti-HER3 Ab	 Generally asymptomatic; however, pruritus and tenderness may occur 	 Presence of papules or pustules Wide distribution; frequently located on face, scalp, upper chest, and back Presence of open comedones has been observed with everolimus, which inhibits another node of the PI3K pathway (mTOR) 	 Histopathology for alpelisib-associated acneiform rash not reported Patients treated with everolimus have presented with eczematous histolog interface dermatitis, spongiosis

Ab, antibody; BC, breast cancer; HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase.

Prevention of Alpelisib-Associated Rash

 Administering prophylactic medication to patients receiving alpelisib before the onset of rash has been shown to reduce the incidence and severity of this adverse event (Figure 1).9-11

Figure 1. Occurrence of rash in patients who received prophylaxis and those who did not



^aNo grade 4 rash was reported in SOLAR-1 or in the retrospective study.

- athological erization^{11,16}
- ial perivascular s with focal or facechange ocentric
- vtic infiltration nology for associated
- treated olimus sented with ous histology,
- interruptions to achieve better therapeutic efficacy.9,11 Management strategies include dermatitis, and
 - Early identification and intervention
 - Patient education
 - Clear guidance on preventive treatment

Management of Alpelisib-Associated Rash

- HCP training on supportive medications and dose adjustment protocols
- In SOLAR-1, more detailed management guidelines introduced after a protocol amendment resulted in a decrease in incidence of grade 3 rash.9

Strategies that both health care professionals (HCPs) and patients can adopt to prevent the onset of

Consider prescribing prophylactic nonsedating antihistamines (10 mg/day cetirizine or loratadine)

• Educate patients on the signs and symptoms of alpelisib-associated rash for early-reporting and

Avoid sun exposure and irritant skin products to prevent worsening of rash, dryness, and itching.

adjustments/interruption (mostly in patients experiencing grade 3 rash; Figure 3).71

HCPs

Patients

Alpelisib-associated rash is generally reversible with adequate co-medication and, if needed, alpelisib dose

interrupted treatment were able to resume alpelisib and did not experience rash recurrence (9 of those

patients were rechallenged with the initial alpelisib dose); 4 patients (25%) experienced rash recurrence

- Retrospective data showed that upon improvement to grade ≤1 rash, 12 of 16 patients (75%) who

Active management of alpelisib-associated rash may help limit dose adjustments and prevent treatment

within 24 hours of alpelisib rechallenge and required permanent alpelisib discontinuation.¹¹

alpelisib-associated rash are described in Figure 2.9-11

to patients starting alpelisib during the first 8 weeks of therapy.

Figure 2. Rash prevention strategies

prompt management.

Maintain proper skin hydration.

Figure 3. Management of alpelisib-associated rash based on severity^{6,7,11,17,18,a}

CTCAE grading	Grade 1 <10% BSA with active skin toxicity.	Grade 2 10%-30% BSA with active skin toxicity.	Grade 3 30% BSA with active skin toxicity.	Grade 4 Life-threatening; any % BSA with extensive superinfectior and IV antibiotics indicated.
Alpelisib dosing	No alpelisib dose adjustment required.		Interrupt alpelisib until improved to grade ≤1.	Permanently discontinue alpelisib.
Supporting medication	 Initiate class I-III topical cortic betamethasone, clobetasol, c If presenting with pruritus or antihistamines in the mornin cetirizine/loratadine) and at or diphenhydramine). If presenting with acneiform causative agents (oral contr medications, dehydroepiand diphenhydramine. 	or fluocinonide). burning sensation, add g (nonsedating: night (sedating: hydroxyzine rash, consider other aceptives, antiandrogen	Follow grade 1/2 supporting medication, and initiate systemic corticosteroids ^b (prednisone ^c , 10-14 days with taper).	
Alpelisib rechallenge	Alpelisib may be resumed at the same dose once rash resolves to grade ≤1, or at a reduced dose at second occurrence. A graded rechallenge with alpelisib may also be considered while maintaining antihistamine treatment and tapering systemic steroids.			

^aEvaluation by a dermatologist familiar with these toxicities is recommended.

^pSystemic corticosteroids may worsen alpelisib-associated hyperglycemia. Caution should be exercised.¹⁹ Methylprednisolone or prednisolone are preferred over prednisone for patients with liver disease. BSA, body surface area; CTCAE, Common Terminology Criteria for Adverse Events; IV, intravenous.

Severe Cutaneous Reactions

- · Life-threatening skin toxicities, such as Stevens-Johnson syndrome (SJS), erythema multiforme (EM), drug reaction with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN) are not common.^{6,11}
- Patients with a history of severe cutaneous reactions should not start alpelisib treatment.⁶
- Symptoms may include a prodrome of fever, flu-like symptoms, mucosal lesions, or progressive skin rash.^e
- Alpelisib should be interrupted if severe cutaneous reactions are suspected, and permanently discontinued if diagnosis is confirmed or grade 4 rash occurs.⁶

Conclusions

- Rash is a frequently observed alpelisib-associated adverse event that can be managed with medication. such as antihistamines and corticosteroids, and alpelisib dose adjustments and interruptions.
- Rash leading to alpelisib treatment discontinuation did not occur frequently in clinical studies and most patients were able to resume anticancer treatment upon rash resolution.
- Preventive strategies, such as administration of prophylactic medication, patient education, early detection of symptoms, and prompt treatment, may help minimize the onset and severity of alpelisib-associated rash.
- Severe cutaneous reactions (SJS, EM, DRESS, and TEN) are not common in patients treated with alpelisib; if suspected, alpelisib should be interrupted, and permanently discontinued if diagnosis is confirmed.

References

- 1. Blows FM, et al. PLoS Med. 2010;7(5):e1000279
- 2. Cancer Genome Atlas Network. Nature. 2012:490(7418):61-70.
- 3. Mollon L, et al. AACR 2018. Poster 1207.
- 4. Mosele F, et al. Ann Oncol. 2020;31(3):377-386.
- 5. Sobhani N, et al. J Cell Biochem. 2018;119(6):4287-4292.
- 6. Pigray [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2019.
- 7. André F, et al. *N Engl J Med*. 2019;380(20):1929-1940.
- 8. Schindler K, et al. J Clin Oncol. 2014;32:e20639.
- 9. Rugo HS, et al. Ann Oncol. 2020;31(8):1001-1010.
- 10. Rugo HS, et al. ASCO 2020. Abstract 1006 (oral).
- 11. Wang DG, et al. Breast Cancer Res Treat. 2020;183(1):227-237.
- 12. U.S. Department of Health and Human Services, NIH, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
- 13. U.S. Department of Health and Human Services, NIH, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03 (CTCAE).
- 14. Nunnery SE, Mayer IA. Ann Oncol. 2019;30(suppl 10):x21-x26.
- 15. Chia S, et al. Curr Oncol. 2015;22(1):33-48.
- 16. Balagula Y. et al. Cancer. 2012:118(20):5078-5083.
- 17. BC Cancer. Provincial Health Services Authority. http://www.bccancer.bc.ca/. Accessed August 31, 2020
- 18. Tan AU, et al. Int J Womens Dermatol. 2017;4(2):56-71.
- 19. Tamez-Perez HL, et al. World J Diabetes. 2015;6(8):1073-1081.

Acknowledgments

Medical editorial assistance was provided by Casandra M. Monzon, PhD, Healthcare Consultancy Group, LLC, and was funded by Novartis Pharmaceuticals Corporation.

Presented at: 2020 Fall Clinical Dermatology Conference. October 29-November 1, 2020 Las Vegas, NV.

Text: Q1ad94

To: 8NOVA (86682) US Only +18324604729 North, Central, and South Americas; Caribbean; China +447860024038 UK, Europe, and Russia

+46737494608 Sweden and Europe

Visit the web at: http://novartis.medicalcongressposters.com/ Default.aspx?doc=1ad94





of the author/presenter.

This presentation is the intellectual property

Contact them at APatel11@mdanderson.org for permission to reprint and/or distribute. Copies of this poster obtained through

Quick Response (QR) Code are for personal use only and may not be reproduced without permission of the authors.